Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems.

Raschi, E

Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. [electronic resource] - Nutrition, metabolism, and cardiovascular diseases : NMCD 06 2018 - 533-542 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

1590-3729

10.1016/j.numecd.2018.02.014 doi


Adverse Drug Reaction Reporting Systems
Clinical Decision-Making
Diabetes Mellitus, Type 2--diagnosis
Humans
Patient Selection
Pharmacovigilance
Risk Assessment
Risk Factors
Sodium-Glucose Transporter 2 Inhibitors--adverse effects
Treatment Outcome